BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels “reflect appropriate risk” for the company’s RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune’s “productive” Type A meeting supports potential approval.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
- Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
- Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
- Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
- Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer